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Abstract 
Background and Aim: Secreted gastric mucins are large O-glycosylated proteins of crude 
mucus gels which are aberrantly expressed in malignancy. An albumin associated 55-65kDa 
glycoprotein was previously shown in mucus gels in gastric cancer. The aim of this study was 
to investigate its expression and identification in human gastric tissue. Methods: Mucins were 
purified from crude mucus scrapings of 16 partial and 11 total resections and a rabbit poly-
clonal antibody was raised to the 55-65kDa glycoprotein. The location and expression of the 
glycoprotein was examined in normal gastric mucosa (n=20), intestinal metaplasia (n=18) and 
gastric cancer (n=27) tissue by immunohistochemistry. Mucins were analyzed by isoelectric 
focusing (IEF) on 2-D polyacrylamide gels. Identification of the 40-50kDa glycoprotein was by 
MALDI-TOF MS technique. Plasma levels were examined by Western blotting. Results: 
Extensive SDS-PAGE analysis gave a PAS positive glycoprotein in the 40-50kDa range, in pa-
tients with gastric cancer but not normals. It was expressed in parietal and columnar cells of 
normal gastric tissue and intestinal metaplasia respectively, and in 22 of 27 gastric cancer 
specimens. In 2-D PAGE stained with Coomassie Blue there were 3 spots positively identified 
as alpha-1-acid glycoprotein (AGP) by MALDI-TOF MS technique. PAS staining revealed a 
single bright spot in the same position but could not be identified. Preliminary measurements 
showed slightly higher levels of AGP in plasma of patients with gastric carcinoma. Conclu-
sion: AGP levels are increased in gastric tissue and in the plasma of those with carcinoma of 
the stomach. 
Key words: Mucus, Mucin, intestinal metaplasia, gastric, cancer, α-1-acid-glycoprotein. 
Introduction 
The gastrointestinal tract is  coated with a pro-
tective  visco-elastic  mucus  gel  synthesized  and  se-
creted by specialized cells in the surface and/or un-
derlying submucosa.1 In the normal gastric mucosa, 
MUC12, MUC43, MUC5AC4 and MUC65 are expressed 
in a characteristic zonal pattern. MUC1 has a mem-
branous staining pattern in the surface epithelium and 
mucus neck zone cell2 whilst MUC4 stained in both 
normal stomach tissue and gastritis3. The distribution 
of MUC5AC is limited to the cytoplasm of the surface 
epithelium and mucus neck cells.6 MUC6 is expressed 
in the cytoplasm of the deep mucus glands and mucus 
neck  cells.5  The  gastric  mucus  gel,  composed  of 
MUC5AC and MUC6,5 protects the gastric epithelia 
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from the shear forces associated with digestion.7  
Gastric cancer, a fatal malignancy with 700,000 
deaths reported annually8 is prevalent in the Western 
Cape  region  of  South  Africa  among  so-called  Cape 
Coloured males (a hybrid race of Western European, 
Southern  African  and  Asian  origin).9-11  Clinical 
markers for early detection of disease include carci-
noembryonic  antigen  (CEA)  and  CA  19-9,  both  of 
which lack specificity12,13 and in the case of CA 19-9, 
detectable more often in the advanced stage of gastric 
carcinoma than in the early stages.14 There has been 
an increasing interest in mucins in the detection and 
treatment of carcinomas in general15 in particular as 
diagnostic and therapeutic agents.16  
Both  our  laboratory17-21  and  another22  reported 
the presence of a clinically useful marker in the crude 
mucus  scrapings  and  gastric  juice  of  gastric  cancer 
patients. It was suggested that this albumin associated 
glycoprotein,  previously  estimated  to  be  of  Mr  ~ 
55-65kDa  and  now  Mr  ~  40-50kDa  with  extensive 
SDS-PAGE analysis, was a fragment of MUC5AC.20 In 
this study the location and expression of this glyco-
protein and mucins in gastric mucosa were studied 
and its identification as α-1-acid glycoprotein (AGP), 
an acute phase protein, established. The levels of AGP 
were preliminarily shown to be slightly higher in the 
bloods of patients undergoing resection for carcinoma 
of the stomach, than in normals.  
Materials and Methods 
Ethics and Patients 
The  University  of  Cape  Town  Research  Ethics 
Committee approved this study (REC REF: 084/2002). 
Twenty seven gastrectomy specimens (16 partial and 
11 total resections) were obtained from patients who 
had  undergone  surgery  between  2005  and  2008  at 
Groote Schuur Hospital (n=23) and the University of 
Cape Town Private Academic Hospital (n=4).  
Collection preparation and analysis of gastric 
mucus 
Crude mucus was scraped from the gastrectomy 
specimens,  solubilized  by  brief  homogenization  in 
ice-cold 6M guanidinium HCl containing a cocktail of 
protease inhibitors, and purified by density gradient 
centrifugation in CsCl twice, as described previous-
ly.20,23  Approximately  500μg  purified  mucin  was 
loaded on 10% SDS-PAGE followed by Western blot-
ting performed as described by Mall et al.24 Nitrocel-
lulose membranes were probed with the polyclonal 
antibody  to  the  40-50kDa  glycoprotein  raised  in  a 
three month old female rabbit by the method of Bell-
stedt et al.25  
Histochemistry and Immunohistochemistry  
Formalin  fixed  paraffin  wax  embedded  gastric 
tissue blocks (matched to the patients that had mucus 
scraped from their stomachs) were obtained from the 
archives  of  the  Division  of  Anatomical  Pathology, 
National Health Laboratory Service (NHLS) - Groote 
Schuur  Hospital.  All  sections  (2µm)  were  routinely 
stained for haematoxylin and eosin and special stains 
for mucin, PAS/AB and HID/AB and assessed by a 
pathologist  (DG).  The  samples  included  3  normal 
mucosa sampled away from the tumour, 17 normal 
mucosa immediately adjacent to tumour, 13 intestinal 
type carcinomas, 7 diffuse carcinomas, 1 mixed intes-
tinal type and diffuse carcinoma, 4 signet ring carci-
nomas and 2 mucinous carcinomas. 
Immunohistochemistry was done with primary 
rabbit polyclonal antibody against the 40-50kDa gly-
coprotein  (diluted  in  PBS  and  HSA),  monoclonal 
mouse  anti  -  MUC1,  MUC1core,  MUC2,  MUC4, 
MUC5AC and MUC6 and rabbit anti-human-albumin 
polyclonal antibody, diluted in PBS, according to Mall 
et al.26 Normal small intestine was used as a positive 
control for the 40-50kDa glycoprotein, normal stom-
ach for MUC1, normal colon for MUC2 and MUC4 
and normal stomach for MUC5AC and MUC6. PBS 
was used instead of the primary antibodies for nega-
tive  control.  Sections  were  then  incubated  with  the 
respective  secondary  antibody  (Envision  anti-rabbit 
HRP  or  anti-mouse  HRP)  and  detection  of  staining 
using DAB. 
2D SDS PAGE of mucin-rich sample prepara-
tions 
This was a slight modification to that described 
by Thomas et al.27 Protein (100 µg for CBB or 200 µg 
for PAS staining), in the mucin-rich preparations, was 
precipitated using TCA/acetone, air dried and then 
resolubilized to a final volume of 125L in urea buffer 
(9M  urea,  2M  thiourea,  4%  (w/v)  3-[(3- 
cholamidopropyl)  dimethylammonio]-1-propanesul-
fonate (CHAPS) and mixed with 0.8% (w/v) dithio-
threitol  (DTT),  0.2%  (v/v)  ampholytes  pH  3-10 
(BIO-RAD,  Hercules,  CA,  USA),  with  0.002%  bro-
mophenol blue. The samples were then used to pas-
sively  rehydrate  7  cm  IPG  linear  strips,  pH  3-10 
(BIO-RAD),  overnight  at  room  temperature.  The 
strips were subjected to isoelectric focusing (IEF) us-
ing  the  EttanTM  IPGphor  IITM  (GE  Healthcare, 
Amersham, UK), in a step-wise programme for a total 
of  12,000Vh  at  20C  for  6h.  Prior  to  the  second  di-
mension, the strips were equilibrated twice for 10 min 
with  gentle  shaking  in  an  equilibration  buffer  (6M 
urea,  2%  (w/v)  SDS,  0.05M  Tris-HCl,  pH  8.8,  20% 
(v/v)  glycerol  and  0.002%  bromophenol  blue)  con- Journal of Cancer 2012, 3 
 
http://www.jcancer.org 
85 
taining 1% (w/v) DTT and then 2.5% (w/v) iodoa-
cetamide.  The  strips  were  then  loaded  on  a  12% 
SDS-PAGE and electrophoresed vertically at 120V for 
90 min. The gels were stained with CBB or PAS and 
imaged with the PharosFXTM plus molecular imager 
scanner (BIO-RAD). 
In-gel digestion and MALDI-TOF MS identifi-
cation of protein spots from 2-D gels 
The CBB and PAS stained 2-D PAGE spots were 
excised  and  manually  plugged  out  with  sterile  cut 
pipette  tips  and  placed  into  sterile  micro-centrifuge 
tubes. Proteins in gel plugs (approximately 2mm in 
diameter and 1mm in height) were trypsinised and 
processed for identification according to the method 
of Thomas et al.27  
Western blots were done of blood samples ob-
tained  from  healthy donors (n=49)  and  patients  un-
dergoing gastrectomy for cancer (n=24) and probed 
with antibody against α-1-acid glycoprotein (AGP).  
Results 
Preparation and analysis of purified mucin  
There  was  a  clear  separation  of  mucin  from 
contaminating  proteins  after  density  gradient  cen-
trifugation in CsCl (result not shown). The purified 
mucin  was  run  on  two  gels,  one  stained  with  PAS 
(Figure 1A) to confirm the presence of the 40-50kDa 
glycoprotein (Figure 1A, lane 6, circled) and mucins 
(Figure 1A, lane 7, arrow), and the other with Ponceau 
S (Figure 1B) from which the 40-50kDa glycoprotein 
was cut just below the region where albumin (Figure 
1B, lane 1, arrow) was visible. In both gels, BSA was 
loaded in lanes 1 and stained positively with Ponceau 
S (Figure 1B) and not with PAS (Figure 1A). 
A strong reactivity to the 40-50kDa glycoprotein 
was  seen  in  purified  mucin  from  a  gastric  cancer 
specimen (Figure 2A, lane 6 arrow). Cross-reactivity 
with  albumin  (Figure  2A,  lanes:  1-5  and  7-8)  was 
abolished with incubation of the antibody with HSA 
prior  to  electrophoresis  leaving  reactivity  only  to 
cancer mucin, presenting as a smear at the top of the 
running  gel  (Figure  2B,  lanes  6  and  9,  arrowhead), 
suggesting non-specific binding of this glycoprotein 
with  mucins  or  the  presence  of  similar  epitopes  in 
both species.  
In  the  lanes  which  were  positive  for  the 
40-50kDa glycoprotein (Figure 2B, lanes 6 and 9), no 
reactivity  was  noted  in  the  region  of  albumin  at 
66-70kDa (lane 9, middle arrowhead) with clear reac-
tivity to the 40-50 kDa glycoprotein (lane 9, bottom 
arrowhead). Very faint material was seen below the 
Mr ~ 40-50kDa band.  
 
 
 
Figure 1. Analysis by SDS-PAGE of purified mucin obtained from specimens resected for gastric cancer. Freeze-dried 
mucin (500 µg) from patients with gastric cancers was prepared in reducing sample application buffer and separated on 10% SDS-PAGE. 
(A) Gel stained with PAS showing the 40-50 kDa glycoprotein (lane 6, circled) and mucin (lane 7, arrow). (B) Gel stained with Ponceau S 
showing the “blob” of albumin (lane 1, arrow). Gels (A) and (B) contain samples in the following order: Lane 1 (200 µg BSA), lane 2 (M, 
55yr, partial gastrectomy, iac), lane 3 (M, 53yr, partial gastrectomy, iac), lane 4 (F, 74yr, partial gastrectomy, dac), lane 5 (M, 60yr, partial 
gastrectomy, srac), lane 6 (F, 57yr, total gastrectomy, dac), lane 7 (M, 60yr, partial gastrectomy, dac). The cut gel was stored at -20°C until 
immunization. (Abbreviations: M – male, F – female, iac – intestinal type carcinoma, dac – diffuse carcinoma, srac – signet-ring cell car-
cinoma)  
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Figure 2. Western blot of the 40-50 kDa glycoprotein. Following two CsCl density gradient steps, purified mucins (300-500 ug) 
and BSA (190-200 ug) were electrophoresed on SDS-PAGE gel (3% stacking gel and 10% running gel). After electrophoresis, proteins 
were transferred onto a nitrocellulose membrane using a semi-dry electroblotting unit for 1h. Membranes were probed using the antibody 
to the 40-50 kDa glycoprotein. Immunoreactivity was detected using an ECL kit and films were processed using a standard X-ray de-
veloper. (A) Primary anti-(40-50 kDa glycoprotein) antibody prepared without human serum albumin (HSA) and showing high cross 
reactivity. Lane 1 (crude PMP), lane 2 (crude PCC), lane 3 (crude PMP), lane 4 (purified FAP), lane 5 (CGC), lane 6 (PGC), lanes 7 and 8 
(BSA). (B) Primary anti-(40-50 kDa glycoprotein) antibody incubated with HSA showing no cross-reactivity. Lane 1 (BSA), lane 2 (PCC), 
lane 3 (CGC), lane 4 (PGC), lane 5 (crude gastric cancer), lane 6 (PGC), lane 7 (purified PMP), lane 8 (purified FAP), lane 9 (PGC) and lane 
10 (BSA). (Abbreviations: PMP - pseudomyxoma peritonei, PCC - purified colon cancer, FAP - familial adenomatous polyposis coli, CGC 
- crude gastric cancer, PGC - purified gastric cancer and BSA - bovine serum albumin) 
 
Immunohistochemical expression of the 
40-50kDa glycoprotein and mucin in normal 
gastric tissue, intestinal metaplasia and gastric 
cancer 
The 40-50kDa glycoprotein was consistently ex-
pressed  in  the  cytoplasm  of  parietal  cells  (20/20) 
(Figure  3A,  arrows).  None  of  the  mucin  antibodies 
used in this study stained parietal cells. MUC1 was 
consistently  expressed  in  the  surface  epithelium, 
mucus  neck  cells  and  in  the  deep  gastric  mucus 
glands  (26/26).  There  was  inconsistent  staining  of 
MUC4 in the surface epithelium (10/26) and in the 
deep  mucus  glands  (5/26).  MUC5AC  consistently 
stained  the  surface  epithelium  (26/26).  MUC6  was 
consistently  expressed  in  the  deep  mucus  glands 
(25/25). MUC1 core and MUC2 were not expressed in 
the normal gastric mucosa. 
Complete intestinal metaplasia was present in 11 
of the 12 cases and incomplete intestinal metaplasia 
was seen in 6 of the 12 cases. Five cases showed both 
complete and incomplete metaplasia and one case had 
only incomplete metaplasia. In intestinal metaplasia, 
the 40-50kDa glycoprotein was consistently expressed 
in the columnar cells in complete (type I) IM (11/11), 
incomplete (type II and III) IM (6/6), (Figure 3B). The 
results for mucin in IM are as follows: in the complete 
(type I) IM there was MUC2 (11/11) (goblet cells only) 
and no MUC1, MUC4, MUC5AC and MUC6. In the 
incomplete IM there was MUC2 (6/6) (goblet cells), 
MUC2  (3/6)  (columnar  cells),  MUC5AC  (6/6)  (co-
lumnar cells) and MUC6 (2/6) (columnar cells) with 
no MUC1 and MUC4.  
The 40-50kDa glycoprotein was consistently ex-
pressed in the intestinal type carcinoma (13/13) (Fig-
ure 3C) and was inconsistently expressed in the dif-
fuse  carcinoma  (4/7),  both  showing  cytoplasmic 
staining (Figure 3D). In the mixed (intestinal and dif-
fuse) carcinoma (1/1), the 40-50kDa glycoprotein was 
expressed in both components. It was also expressed 
in the signet-ring cell (2/4) and mucinous (2/2) car-
cinomas. 
MUC1 was expressed in the intestinal (12/13), 
diffuse (7/7) type carcinomas, in both components of 
the  mixed  (1/1)  (intestinal  and  diffuse),  signet-ring 
cell  (4/4)  and  in  the  mucinous  carcinomas  (2/2). 
MUC1 core was expressed in the intestinal (10/13), 
diffuse (1/7), in both components of the mixed (1/1), 
in the signet-ring cell (2/4) and in the mucinous car-
cinomas (2/2). MUC2 was expressed in the intestinal 
(2/13), diffuse (2/7), signet-ring cell (3/4) and in the 
mucinous carcinomas (1/2) and not in the mixed car-
cinoma. MUC4 was expressed in the intestinal type 
(8/13), in the diffuse type (2/7) and in both compo-
nents of the mixed (1/1) carcinomas and not in the 
signet-ring cell and mucinous carcinomas. MUC5AC 
was  expressed  in  the  intestinal  type  (6/13),  in  the 
diffuse type (3/7) and in the signet-ring cell carcino-
mas (3/4) and not in the mixed and in the mucinous 
carcinomas.  MUC6  was  expressed  in  the  intestinal 
type (4/13), in the diffuse type (1/7) and in the sig-
net-ring cell carcinomas (1/4) but  not in the  mixed  Journal of Cancer 2012, 3 
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and the mucinous carcinomas. 
Normal  stomach  expressed  neutral  mucins. 
There  was  a  decrease  of  neutral  mucin  in  IM  with 
sialomucins  predominant  in  the  complete  IM  and 
both sialomucins and sulphomucins in the incomplete 
IM (results not shown). 
Detection of total proteins and glycoproteins 
from mucin samples by 2-D gel electrophoresis 
Three  (spots  1-3)  well-resolved  and  closely 
aligned spots with approximate molecular weights of 
50kDa and a pI between 3 and 4 were detected after 
CBB staining of the 2D gel (Figure 4A).  
The two spots resolved on the more acidic side of 
the gel were of greater abundance than the third spot. 
The three spots differ slightly, not only in their pI, but 
also in their molecular weight, with the most acidic 
spot displaying a slightly higher mass than the second 
spot and the second one higher than the third. Fol-
lowing  PAS  staining,  only  one  single  spot  (spot  4) 
with a molecular weight of approximately 50kDa and 
a pI close to 4 was visualized on the 2D gel (Figure 
4B).  
Protein identification by MALDI-TOF MS  
The  list  of  experimental  peptide  masses  was 
compared  against  the  theoretical  tryptic  digest  of 
every  protein  in  the  MSDB  and  NCBI  databases 
through the MASCOT software. Spots 1, 2 and 3 were 
positively identified, as defined by significant proba-
bility-based MOWSE scores between 67-73 as human 
alpha-1-acid  glycoprotein  (AGP;  Table  1).  Although 
spot  4  digested  well,  as  shown  and  defined  by  the 
abundance of peptides and a high signal to noise ra-
tio, the MOWSE score obtained was lower than 64, 
which falls below the threshold, and the protein was 
thus  not  positively  identified.  When  comparing  the 
list of protein peptides obtained from spots 1, 2 and 3 
(Figure 4) with the peptides from spot 4 (Table 2), the 
profiles looked similar with at least 10 identical pep-
tide masses, highlighted with a bold font. Tryptic di-
gest peptide masses obtained three spots 1, 2 and 3 
which  were  all  positively  matched  to  alpha-1-acid 
glycoprotein  1  precursor.  The  inability  to  obtain  a 
positive  hit  from  tryptic  digest  peptides  generated 
from spot 4 suggests that the PAS protein staining is 
incompatible with the MALDI-TOF mass spectromet-
ric method of protein identification.  
 
Figure 3. Immunodetection of the 40-50 kDa glycoprotein in normal, intestinal metaplasia and gastric cancer tissue. (A) 
Extensive staining of parietal cells (x40, black arrows) was consistently seen on normal tissue sections (normal adjacent to tumour) stained 
with the anti-(40-50 kDa glycoprotein) antibody. This was also observed in the control tissues sampled away from cancer. (B) The 40-50 
kDa glycoprotein was expressed in the cytoplasm of columnar cells in complete and incomplete (not shown) IM but not in the goblet cells 
(x40). (C) The 40-50 kDa glycoprotein was expressed in the cytoplasm of neoplastic glands in the intestinal type carcinoma (x40) and (D) 
by cancer cells of the diffuse type shown invading the muscle wall of the stomach (x20).   Journal of Cancer 2012, 3 
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Figure 4. Two-dimensional gel electrophoresis of purified mucin protein sample from gastric cancer specimens. Purified 
mucin sample (100 µg for CBB and 200 µg for PAS) from gastric cancer specimens was separated using linear 7 cm IPG strips, pH range 
3-10 in the first dimension and 12% SDS-PAGE in the second dimension. Gels were then stained with (A) Coomassie Brilliant Blue showing 
three protein spots (arrows 1, 2 and 3). (B) PAS showing one glycoprotein spot (arrow 4). 
 
Figure 5. Mass spectra obtained by MALDI-TOF MS for the digested protein spots visualized on 2D gel after CBB 
staining. After CBB staining of the 2D gel of purified mucin protein samples from gastric cancer individuals, spots 1, 2 and 3 (Figure 4A) 
were manually excised from the gel, digested with trypsin, and analyzed by MALDI-TOF MS for spectrum acquisition. Using the mass of the 
obtained peptides, the proteins were identified using the Mascot database. Spectra obtained for spots 1, 2 and 3 were similar.  Journal of Cancer 2012, 3 
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Table 1. Recapitulative table of protein spots identified by MALDI-TOF MS. Mucin proteins were identified by 
MALDI-TOF-MS. The table lists the spot number, corresponding to the numbers in Figure 5, accession number, protein 
name, species, theoretical and observed molecular weights (kDa) and pI, MOWSE score (number greater than 64 being 
significant at p<0.05) and the sequence coverage of the positive identification. 
Protein Spot 
number 
Pl from data-
base 
Pl from gel  Molecule weight 
from database (kDa) 
Molecule weight 
from gel (kDa) 
Mowse 
Score 
Name of protein identified 
1  4.92  3-4  46.994  40-50  68  Alpha-1-acid glycoprotein 1 precursor 
[validated]-human 
2  4.93  3-4  46.994  40-50  64  Alpha-1-acid glycoprotein 1 precursor 
[validated]-human 
3  4.93  3-4  46.994  40-50  67  Alpha-1-acid glycoprotein 1 precursor 
[validated]-human 
 
 
Table 2. Tryptic peptide mass peak list for each spot analyzed by MALDI-TOF MS. Coomassie (spot 1-3) and 
PAS stained (spot 4) protein were analyzed by MALDI-TOF MS. The table lists tryptic digest peptide masses (m/z) for each 
of the four protein spots. Masses shared by spot 4 and at least one other from the spots identified as AGP (spot 1-3). 
 
Spot 1  Spot 2  Spot 3  Spot 4 
      1002.5854 
1112.5379       
1144.5245      1144.6054 
      1158.6726 
1160.5976  1160.6009  1160.6106  1160.6790 
      1164.6668 
1176.5922      1176.6702 
    1179.6230  1179.6781 
1192.5896  1192.5866    1192.6728 
1234.7168    1234.7171  1234.7904 
1277.7423       
1307.6946    1307.7095   
1445.6883       
      1461.8276 
1475.7815  1475.7568  1475.7768   
      1633.8864 
1651.8197  1651.7785    1651.9035 
1657.8168    1657.8257  1657.9082 
      1668.9096 
1685.8064  1685.7597  1685.7997  1685.9017 
1699.8418       
      1701.8680 
      1703.8405 
    1707.7905   
1708.8478  1708.7901  1708.7954   
1716.8704       
1724.8238  1724.7471  1724.7937   
1725.8136       
1726.7949    1726.7877   
1742.8295  1742.7520  1742.8043  1741.8838 
1744.0956       
Spot 1  Spot 2  Spot 3  Spot 4 
       
    1746.8055   
1752.9635  1752.8899  1752.9530  1753.0573 
1756.8420  1756.7619  1756.8323   
      1758.9559 
      1842.0540 
1784.9557       
1868.7568    1868.7870   
1888.0296       
      1931.0856 
      1936.9104 
1994.0182    1940.9774   
  2021.8990     
  2094.8900     
  2096.9331     
  2112.9138     
  2126.9287     
  2021.8990     
    2225.1416   
    2239.1893   
2384.0306       
    2510.1669   
2717.1665       
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Preliminary  studies  show  that  blood  levels  of 
AGP  are  variably  increased  in  patients 
pre-operatively compared to levels in normal bloods 
(Figure 6). 
 
 
 
Figure 6. Western blot analysis after 10% SDS-PAGE of 
AGP in bloods of patients pre-operatively compared to 
that from blood donors. Lane 1, purified mucin from patient 
with pseudomyxoma peritonei, Lane 2, donor blood, Lanes 3-5, 
blood from patients undergoing gastrectomy for carcinoma of the 
stomach. 
 
Discussion 
This  study  was  limited  by  the  infrequency  of 
surgical resections (inoperability because of advanced 
disease), low yields of purified mucin per sample, a 
lack  of  suitable  normal  tissue  due  to  new  foren-
sic-legal regulations governing the use of tissue from 
cadavers and transplant donors and the inexplicable 
absence of the glycoprotein in some samples.  
Mucins  were  extracted  from  crude  mucus 
scrapings in denaturing media and the fractionation 
of the 40-50kDa glycoprotein with mucin during pu-
rification in a CsCl density gradient indicated that it 
was extensively glycosylated and could only be sep-
arated from mucins and albumin upon heating in SDS 
or by gel filtration.20 The glycoprotein was absent in 
crude mucus scrapings from cadaver and transplant 
donor stomachs.20 
The  close  association  of  this  glycoprotein  with 
albumin, shown  here and previously,17-20 even after 
two or sometimes three purification steps in a density 
gradient centrifugation in CsCl (Mall, personal com-
munication), complicated attempts to isolate it in its 
pure form. Although stomachs of patients with gastric 
cancer are likely to have increased amounts of albu-
min, through leakage of serum into the stomach,20, 28 
we are unable to explain  why albumin was not re-
moved during the purification process in 3.5M CsCl.  
The 40-50kDa glycoprotein was best visualized 
by staining the gel with PAS,29 which then made it 
unsuitable  for  immunization  (Bellstedt,  personal 
communication).  Ponceau  S  staining  detected  albu-
min and made easier the localization of the 40-50kDa 
glycoprotein,  which  always  appeared  immediately 
below albumin. To counteract reactivity with albumin 
(Figure 2A), the antibody was incubated with HSA for 
1 h prior to electrophoresis. The reactivity of the an-
tibody with larger mucins at the top of the running gel 
could be due to shared epitopes between them (Figure 
2B, Lane 4), as shown previously20,30. 
This study was more definitive than the previous 
ones17-20 in that those studies relied on the investiga-
tion of this glycoprotein in crude mucosal scrapings 
and gastric juice,21 and did not distinguish between 
normal  and  tumour  portions  of  the  mucosa.  Im-
munohistochemical  findings  showed  the  expression 
of the 40-50kDa glycoprotein in normal tissue, with 
increasing amounts in intestinal metaplasia and can-
cer.  Parietal  cell  staining  in  normal  gastric  mucosa 
was  the  first  surprising  hint  that  this  glycoprotein 
may not be a mucin, as thought previously.20 In intes-
tinal metaplasia and normal small intestine, the gly-
coprotein  was  found  in  the  cytoplasm  of  columnar 
cells, and not in the mucus secreting goblet cells. The 
lack of tissue prevented us from examining the ex-
pression of the glycoprotein in all forms of metaplasia. 
In types I and II IM however, there was no difference 
in  the  expression  of  the  glycoprotein.  In  this  study 
and the previous one20 the cancers were mostly of the 
intestinal  and  diffuse  type  carcinomas  with  fewer 
signet,  mucinous  and  mixed  intestinal  and  diffuse 
type carcinomas.  
Our results also confirmed previous findings of 
the cellular and tissue distribution of MUC5AC in the 
surface epithelium,6 MUC6 in the deep mucus glands 
and mucus neck cells5, MUC1 in the mucus cells of the 
surface epithelium and in the glands of the body2 and 
MUC4 in normal gastric mucosa.3 There was no ex-
pression of MUC1core and MUC2 in the normal gas-
tric mucosa. 
The combination of 2D gel electrophoresis and 
MALDI-TOF MS analyses led to a successful identifi-
cation  of  this  glycoprotein  as  AGP.  An  amino  acid 
analysis suggested the glycoprotein is N-linked20, 21, 
thus supporting its identification as AGP, which has 
been reported as a marker of disease in the blood of 
patients with carcinoma of the lung, breast, ovary 31,32 
and liver.33  Journal of Cancer 2012, 3 
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The  immunomodulatory  functions  of  AGP  are 
physiological mechanisms meant to dampen the im-
mune response and prevent unnecessary damage to 
nearby tissues during acute inflammation.34 However, 
during  malignant  transformation,  the  presence  of 
AGP may confer unfair advantages to neoplastic cells 
such  as  protecting  cells  from  apoptosis  induced  by 
inflammation.35 Aberrant glycosylation of AGP sug-
gests it to be a strong candidate as a marker of the 
progression  and  prognosis  of  various  cancers,  with 
various glycoforms containing highly fucosylated tri- 
and  tetra-antennary  oligosaccharide  side-chains  at 
increased  levels  long  after  surgery,  indicative  of  a 
poor prognosis.36 The role of AGP in the pathogenesis 
of gastric cancer is uncertain and its importance as a 
marker  for  pre-malignant  disease  requires  further 
investigation.  However,  preliminary  studies  have 
shown that there is a slight increase in the blood levels 
of AGP in patients prior to and soon after surgery. 
This  observation  is  being  further  explored  with  the 
aim  of  following  up  a  larger  group  of  patients  for 
longer periods. 
Although the CBB stained spots 1, 2 and 3 (Fig-
ure 4) were positively identified, tryptic digest pep-
tides from spot 4 produced no positive hit in the pro-
tein databases, suggesting that its extensive glycosyl-
ation or PAS staining hindered digestion by trypsin 
(results not shown). Either of these factors could have 
caused  chemical  mass  shifts  which  affected  the 
measured  protein/peptide  mass.  Measured  tryptic 
peptide masses obtained for spots 1, 2 and 3 are very 
similar to those obtained from spot 4, particularly for 
three  peptides  that  matched  to  alpha-1-acid  glyco-
protein 1 precursor. This suggests that spot 4 might be 
a more glycosylated isoform of this protein.  
The  isoelectric  point  (pI)  of  the  identified  al-
pha-1-acid  glycoprotein  (AGP),  predicted  in  silico 
based on the amino acid sequence is 4.93. This is con-
gruent with the pI 3-4 observed in our study, and the 
slight  shift  is  most  likely  due  to  post-translational 
modifications (Figure 5; Table1). On the other hand, 
the  observed  50  kDa  molecular  weight  is  twice  the 
theoretical prediction (23kDa). Fifty percent of AGP is 
glycosylated37 and when treated with N-glycosidase F 
its molecular weight is reduced to 23 kDa.  
Identification of the glycoprotein as AGP, facili-
tates a study of its suitability as a clinical marker for 
pre-malignancy  in  a  high-risk  population  in  the 
Western Cape region of South Africa. We have begun 
a study to detect its levels in the blood of patients with 
cancer.  Alternative  MS  compatible  glycoprotein 
staining methods to visualize and identify spot 4 are 
also underway. 
Abbreviations: 
CsCl: Caesium chloride; IM: Intestinal metapla-
sia;  PAS:  Periodic  acid  Schiff;  SDS-PAGE:  Sodium 
dodecyl sulphate polyacrylamide gel electrophoresis; 
HCl: Hydrochloric acid; EDTA: ethylene diamine tet-
ra acetic acid; NEM-N: ethylmaleimide; PMSF: phe-
nylmethylsulfonylfluoride;  DTT:  dithiothreitol; 
GuHCl:  guanidinium  hydrochloride;  IEF:  Isoelectric 
focusing;  AGP:  Alpha-1:  acid  glycoprotein;  CBB: 
Coomassie  Brilliant  Blue;  MS:  Mass  spectrometry; 
MALDI-TOF:  Matrix  assisted  laser  desorp-
tion/ionization:time of flight; AB: Alcian Blue; HID: 
High iron diamine. 
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